Kventiax (Quetiapine)

Quetiapine works by blocking several neurotransmitter receptors, notably serotonin 5‑HT2A and dopamine D2 receptors, as well as histamine H1 and adrenergic α1 receptors. This combined antagonism helps to balance dopamine and serotonin activity, reducing psychotic symptoms and stabilising mood.

The appropriate dose of Kventiax is determined by the prescribing clinician based on the individual patient's diagnosis, severity of symptoms, response to therapy and any relevant medical conditions. Dosage adjustments are made according to clinical judgment and patient tolerance.

Safety data for quetiapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should discuss individual risks and consider alternative treatments when appropriate.

To request Kventiax, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kventiax (quetiapine) shares the broad receptor‑blocking profile typical of atypical antipsychotics but is distinguished by its relatively lower affinity for dopamine D2 receptors, which may result in a lower risk of extrapyramidal symptoms. Its sedating properties are more pronounced, making it useful for patients with insomnia or agitation.

Kventiax should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Kventiax is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include orthostatic hypotension, neuroleptic malignant syndrome, tardive dyskinesia, significant metabolic changes such as hyperglycaemia, and the emergence or worsening of suicidal thoughts, especially during early treatment or dose changes.

Kventiax is contraindicated in patients with known hypersensitivity to quetiapine or any of its excipients. Caution is advised for individuals with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of neuroleptic malignant syndrome. The medication should be avoided in patients where the risk outweighs the therapeutic benefit.